CD38 and COVID-19: As reported in Fig. 4c, showing the statistical analysis of chemokine receptors and master regulators in patients vs. controls, COVID-19 patients were characterized by higher percentages of terminal effector cells expressing CD38 alone or in combination with CD57, and by activated effector memory cells expressing PD1 or CD57.